Vaccine Preventable Diseases and Vaccination Coverage in Aboriginal and Torres Strait Islander People, Australia, 2016–2019

Jackson, J. B. S.; Sonneveld, Nicole; Rashid, Harunor; Karpish, Larissa; Wallace, Seaneen; Whop, Lisa J.; Patel, Cyra; Brotherton, Julia; Han, Wei; Hendry, Alexandra; Hull, Brynley P; Clark, Katrina; Lambert, Stephen; Dey, Aditi; Beard, Frank

doi:10.33321/cdi.2023.47.32

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Missed opportunities for vaccination occur when a patient presents at a medical practice but does not receive the vaccines they are due, and CDSS technology can improve adherence to clinical guidelines and vaccination rates [18]. While health technology is utilised with success using patient‐focused recall and reminders for on‐time vaccination, especially in infants, such as SMS reminders [19–21], it is a provider‐centred initiative focusing on recommending vaccines, consistently at all possible clinical encounters to improve vaccination uptake. Most of the medical practices in our study relied on their own method of recalling patient's vaccination history; however, there is evidence that CDSS technology can improve vaccination rates [22].…”

Section: Discussionmentioning

confidence: 99%

Evaluating Pilot Implementation of ‘PenCS Flu Topbar’ App in Medical Practices to Improve National Immunisation Program–Funded Seasonal Influenza Vaccination in Central Queensland, Australia

Khandaker,

Chapman,

Khan

et al. 2024

Influenza Resp Viruses

View full text Add to dashboard Cite

BackgroundThe ‘PenCS Flu Topbar’ app was deployed in Central Queensland (CQ), Australia, medical practices through a pilot programme in March 2021.MethodsWe evaluated the app's user experience and examined whether the introduction of ‘PenCS Flu Topbar’ in medical practices could improve the coverage of NIP‐funded influenza vaccinations. We conducted a mixed‐method study including a qualitative analysis of in‐depth interviews with key end‐users and a quantitative analysis of influenza vaccine administrative data.Results‘PenCS Flu Topbar’ app users reported positive experiences identifying patients eligible for NIP‐funded seasonal influenza vaccination. A total of 3606 NIP‐funded influenza vaccinations was administered in the eight intervention practices, 14% higher than the eight control practices. NIP‐funded vaccination coverage within practices was significantly higher in the intervention practices (31.2%) than in the control practices (27.3%) (absolute difference: 3.9%; 95% CI: 2.9%–5.0%; p < 0.001). The coverage was substantially higher in Aboriginal and Torres Strait Islander people aged more than 6 months, pregnant women and children aged 6 months to less than 5 years for the practices where the app was introduced when compared to control practices: incidence rate ratio (IRR) 2.4 (95% CI: 1.8–3.2), IRR 2.7 (95% CI: 1.8–4.2) and IRR 2.3 (1.8–2.9) times higher, respectively.ConclusionsOur evaluation indicated that the ‘PenCS Flu Topbar’ app is useful for identifying the patients eligible for NIP‐funded influenza vaccination and is likely to increase NIP‐funded influenza vaccine coverage in the eligible populations. Future impact evaluation including a greater number of practices and a wider geographical area is essential.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluating Pilot Implementation of ‘PenCS Flu Topbar’ App in Medical Practices to Improve National Immunisation Program–Funded Seasonal Influenza Vaccination in Central Queensland, Australia

Khandaker,

Chapman,

Khan

et al. 2024

Influenza Resp Viruses

View full text Add to dashboard Cite

show abstract

“…4 Strategies to improve cervical screening and HPV vaccination uptake for Indigenous women in Latin America and the Caribbean: recommendations for action Cervical cancer poses a significant public health challenge for Indigenous women globally, demanding targeted strategies in response to the unique cultural and systemic factors hindering cervical screening and HPV vaccination uptake in Indigenous populations. Canada, Australia and New Zealand have implemented specific programs and initiatives of cancer screening and/or HPV vaccination that are showing promising results in reducing HPV-related diseases among Indigenous populations (97,(115)(116)(117)(118)(119)(120)(121). While taking example from these successful policies and strategies, it is imperative to devise solutions adapted to the socio-economic realities of LAC countries and the cultural diversity within Indigenous populations residing in the region.…”

Section: Cultural Factorsmentioning

confidence: 99%

Addressing the burden of cervical cancer for Indigenous women in Latin America and the Caribbean: a call for action

Muslin

2024

Front. Public Health

View full text Add to dashboard Cite

Cervical cancer, primarily caused by human papillomavirus (HPV) infection, poses a significant global health challenge. Due to higher levels of poverty and health inequities, Indigenous women worldwide are more vulnerable to cervical cancer than their non-Indigenous counterparts. However, despite constituting nearly 10% of the population in Latin America and the Caribbean (LAC), the true extent of the burden of cervical cancer among Indigenous people in this region remains largely unknown. This article reviews the available information on cervical cancer incidence and mortality, as well as HPV infection prevalence, among Indigenous women in LAC. The limited existing data suggest that Indigenous women in this region face a heightened risk of cervical cancer incidence and mortality compared to non-Indigenous women. Nevertheless, a substantial knowledge gap persists that must be addressed to comprehensively assess the burden of cervical cancer among Indigenous populations, especially through enhancing cancer surveillance across LAC countries. Numerous structural, social and cultural barriers hindering Indigenous women’s access to HPV vaccination and cervical cancer screening worldwide have been identified and are reviewed in this article. The discussion highlights the critical role of culturally sensitive education, community engagement, and empowerment strategies in overcoming those barriers. Drawing insights from the success of targeted strategies in certain high-income countries, the present article advocates for research, policies and healthcare interventions tailored to the unique context of LAC countries.

show abstract

“… 84 85 Unfortunately, these are the populations who have the lowest coverage of existing routine vaccines of childhood. 86–88 This is another manifestation of the inverse care law where those in greatest need are least well served. Delivering high coverage with StrepA vaccines will therefore need well-developed strategies and programmes that draw on the best available evidence about what works to achieve high coverage with existing vaccines delivered to these population and in these settings.…”

Section: Key Research Topicmentioning

confidence: 99%

Research opportunities for the primordial prevention of rheumatic fever and rheumatic heart disease—streptococcal vaccine development: a national heart, lung and blood institute workshop report

Fulurija,

Cunningham,

Korotkova

et al. 2023

BMJ Glob Health

View full text Add to dashboard Cite

Streptococcus pyogenes,also known as group A streptococcus (StrepA), is a bacterium that causes a range of human diseases, including pharyngitis, impetigo, invasive infections, and post-infection immune sequelae such as rheumatic fever and rheumatic heart disease. StrepA infections cause some of the highest burden of disease and death in mostly young populations in low-resource settings. Despite decades of effort, there is still no licensed StrepA vaccine, which if developed, could be a cost-effective way to reduce the incidence of disease. Several challenges, including technical and regulatory hurdles, safety concerns and a lack of investment have hindered StrepA vaccine development. Barriers to developing a StrepA vaccine must be overcome in the future by prioritising key areas of research including greater understanding of StrepA immunobiology and autoimmunity risk, better animal models that mimic human disease, expanding the StrepA vaccine pipeline and supporting vaccine clinical trials. The development of a StrepA vaccine is a complex and challenging process that requires significant resources and investment. Given the global burden of StrepA infections and the potential for a vaccine to save lives and livelihoods, StrepA vaccine development is an area of research that deserves considerable support. This report summarises the findings of the Primordial Prevention Working Group-VAX, which was convened in November 2021 by the National Heart, Lung, and Blood Institute. The focus of this report is to identify research gaps within the current StrepA vaccine landscape and find opportunities and develop priorities to promote the rapid and successful advancement of StrepA vaccines.

show abstract

Vaccine Preventable Diseases and Vaccination Coverage in Aboriginal and Torres Strait Islander People, Australia, 2016–2019

Cited by 4 publications

References 0 publications

Evaluating Pilot Implementation of ‘PenCS Flu Topbar’ App in Medical Practices to Improve National Immunisation Program–Funded Seasonal Influenza Vaccination in Central Queensland, Australia

Evaluating Pilot Implementation of ‘PenCS Flu Topbar’ App in Medical Practices to Improve National Immunisation Program–Funded Seasonal Influenza Vaccination in Central Queensland, Australia

Addressing the burden of cervical cancer for Indigenous women in Latin America and the Caribbean: a call for action

Research opportunities for the primordial prevention of rheumatic fever and rheumatic heart disease—streptococcal vaccine development: a national heart, lung and blood institute workshop report

Contact Info

Product

Resources

About